-
Sector Analysis
Parkinson's Disease in 68 Markets - Disease Overview, Product Profiles, Patient Flow, Competitive Assessment and Sales Forecast to 2033
This report covers the 68 geographical markets and provides an Excel-based forecast model for the Parkinson's Disease market through 2033. GlobalData estimates that drug sales for PD in 2023 were approximately $3.4 billion across the 7MM. With an estimated $2.1 billion in drug sales in 2023, the US dominated the PD market, contributing 63.3% of the sales in the 7MM. The high market share is primarily due to the large PD prevalent population coupled with the cost of drugs, which...
-
Sector Analysis
Alzheimer’s Disease (AD) Epidemiology Analysis and Forecast to 2033
Alzheimer’s Disease (AD) Report Overview In the 8MM, there were 15,987,619 total prevalent cases of Alzheimer’s disease (AD) in 2023. The total prevalent cases of AD will register an AGR of more than 4% during 2023-2033. Alzheimer’s disease (AD) is a progressive neurodegenerative disorder marked by cognitive and behavioral impairment that significantly interferes with social and occupational functioning. It is typically characterized by memory loss, cognitive impairment, functional decline, and gradual inability in performing daily tasks independently. Although the exact...
-
Sector Analysis
Parkinson’s Disease Epidemiology Analysis and Forecast to 2033
Parkinson’s Disease Report Overview In the 7MM, there were 2,636,930 diagnosed prevalent cases of Parkinson’s Disease in 2023. The market will register an AGR of more than 1% during 2023-2033. This increase in the cases of PD across the 7MM is primarily attributed to changes in the underlying population demographics. Parkinson’s disease (PD) is an incurable neurodegenerative disease clinically categorized as a movement disorder with prominent motor symptoms, including tremors, rigidity, and bradykinesia. The clinical presentation of PD is characterized...
-
Product Insights
Idiopathic Hypersomnia (IH) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Idiopathic Hypersomnia (IH) Clinical Trial Report Overview A total of 42 idiopathic hypersomnia (IH) clinical trials were conducted as of October 2024. The idiopathic hypersomnia (IH) clinical trial report offers a comprehensive understanding of disease clinical trials across regions, and countries (G7 & E7). It also provides insights into the various phases, trial status, and end points status. Furthermore, the report includes information about the sponsor types and the prominent sponsors associated with the trials. Key Regions ·      Asia-Pacific ·      ...
-
Sector Analysis
Multiple System Atrophy (MSA) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Multiple System Atrophy (MSA) Marketed and Pipeline Drugs Report Overview MSA is a rare, sporadic, progressive neurological disorder characterized by various symptoms and signs. There is about one living case of MSA in the population for every 40 cases of Parkinson’s disease (PD). However, survival in MSA is shorter than for PD, with about one new MSA case diagnosed each year for every 20 new PD cases. The MSA marketed and pipeline drugs market research report includes an assessment of...
-
Product Insights
Delirium Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Delirium Clinical Trial Report Overview A total of 964 delirium clinical trials were conducted as of August 2024. The delirium clinical trial report provides a comprehensive understanding of the delirium clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor types and the prominent sponsors associated with the trials. Key Regions ·      Asia-Pacific ·      North America ·      Europe ·      ...
-
Product Insights
Metachromatic Leukodystrophy (MLD) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
GlobalData's clinical trial report, “Metachromatic Leukodystrophy (MLD) - Global Clinical Trials Review, 2024" provides an overview of Metachromatic Leukodystrophy (MLD) Clinical trials scenario. This report provides top line data relating to the clinical trials on Metachromatic Leukodystrophy (MLD). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model - Camrelizumab in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Camrelizumab in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Camrelizumab in Triple-Negative Breast Cancer (TNBC) Drug Details: Camrelizumab...
-
Sector Analysis
Frontotemporal Dementia Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
This reports provides a data-driven overview of the current and future competitive landscape in Frontotemporal Dementia therapeutics. • In 2024, more than 700,000 diagnosed prevalent cases of FTD are anticipated in the 16 countries covered in GlobalData’s epidemiology forecast for FTD. • There are currently no approved therapies for FTD in the market. • The FTD pipeline is notably sparse, with no assets in the pre-registration stage, a single asset in Phase III development. • Over the past 10 years,...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model - Rhenium (186Re) Obisbemeda in Leptomeningeal Disease (Neoplastic Meningitis, Leptomeningeal Carcinomatosis)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Rhenium (186Re) Obisbemeda in Leptomeningeal Disease (Neoplastic Meningitis, Leptomeningeal Carcinomatosis) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Rhenium (186Re) Obisbemeda in Leptomeningeal...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.